Harmony Biosciences Holdings, Inc. (HRMY)

Market Cap	2.93B
Revenue (ttm)	400.76M
Net Income (ttm)	155.67M
Shares Out	59.32M
EPS (ttm)	2.56
PE Ratio	19.27
Forward PE	25.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	424,836
Open	48.93
Previous Close	48.84
Day's Range	48.13 - 50.42
52-Week Range	33.04 - 62.09
Beta	0.63
Analysts	Buy
Price Target	67.19 (+36.18%)
Earnings Date	Feb 27, 2023

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvani...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 19, 2020
• Employees: 180
• Stock Exchange: NASDAQ
• Ticker Symbol: HRMY

Analyst Forecast

According to 14 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price forecast is $67.19, which is an increase of 36.18% from the latest price.

Price Target

$67.19

(36.18% upside)

Analyst Consensus: Buy